Pharmacological characterization of Ro 63-1908 (1-[2-(4-hydroxy-phenoxy)-ethyl]-4-(4-methyl-benzyl)-piperidin-4-ol), a novel subtype-selective N-methyl-D-aspartate antagonist

Journal of Pharmacology and Experimental Therapeutics

Volumn 302, Issue 3, 2002, Pages 940-948

  Gill, R ^a   Alanine, A ^a   Bourson, A ^a   Buttelmann, B ^a   Fischer, G ^a   Heitz, M P ^a   Kew, J N C ^a   Levet Trafit, B ^a   Lorez, H P ^a   Malherbe, P ^a   Miss, M T ^a   Mutel, V ^a   Pinard, E ^a   Roever, S ^a   Schmitt, M ^a   Trube, G ^a   Wybrecht, R ^a   Wyler, R ^a   Kemp, J A ^a  

^a F HOFFMANN LA ROCHE LTD   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

1 [2 (4 HYDROXYPHENOXY)ETHYL] 4 (4 METHYLBENZYL)PIPERIDIN 4 OL; 2 AMINO 5 PHOSPHONOVALERIC ACID; 4 BENZYL ALPHA (4 HYDROXYPHENYL) BETA METHYL 1 PIPERIDINEPROPANOL; 6 NITRO 7 SULFAMOYLBENZO[F]QUINOXALINE 2,3 DIONE; DIZOCILPINE; FLUNARIZINE; GLUCOSE; IFENPRODIL; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; N METHYL DEXTRO ASPARTIC ACID RECEPTOR 1C; N METHYL DEXTRO ASPARTIC ACID RECEPTOR 2B; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; OXYGEN; PIPERIDINE DERIVATIVE; RECEPTOR SUBUNIT; RO 63 1908; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTICONVULSANT ACTIVITY; ARTICLE; BINDING AFFINITY; BINDING SITE; BRAIN ISCHEMIA; CARDIOVASCULAR DISEASE; CONTROLLED STUDY; DOSE CALCULATION; DOSE RESPONSE; DOSE TIME EFFECT RELATION; DRUG MECHANISM; DRUG RECEPTOR BINDING; HUMAN; IC 50; INHIBITION KINETICS; MOUSE; NEUROLOGICAL COMPLICATION; NEUROPROTECTION; NEUROTOXICITY; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; SEIZURE; TASK PERFORMANCE;

ACOUSTIC STIMULATION; ALGORITHMS; ANIMALS; ANTICONVULSANTS; BRAIN; CEREBRAL CORTEX; ELECTROPHYSIOLOGY; EXCITATORY AMINO ACID ANTAGONISTS; INFARCTION, MIDDLE CEREBRAL ARTERY; MACACA FASCICULARIS; MALE; MICE; MOTOR ACTIVITY; NEURONS; NEUROPROTECTIVE AGENTS; OOCYTES; PHENOLS; PIPERIDINES; PSYCHOMOTOR PERFORMANCE; RATS; RECEPTORS, N-METHYL-D-ASPARTATE; SEIZURES; VACUOLES; XENOPUS;

EID: 0036720776     PISSN: 00223565     EISSN: None     Source Type: Journal    
DOI: 10.1124/jpet.102.034322     Document Type: Article

References (43)

1. Aptiganel hydrochloride in acute ischemic stroke: A randomized controlled trial
2. Identification of amino acid residues of the NR2A subunit that control glutamate potency in recombinant NR1/NR2A NMDA receptors
3. Kinetic analysis of antagonist action at N-methyl-D-aspartic acid receptors. Two binding sites each for glutamate and glycine
4. An open-label study of CP-101,606 in subjects with a severe traumatic head injury or spontaneous intracerebral hemorrhage
5. Ifenprodil and eliprodil: Neuroprotective NMDA receptor antagonists and calcium channel blockers
6. (1S,2S)-1 -(4-Hydroxyphenyl)-2-(4-hydroxy-4-phenylpiperidino)-l-propanol: A potent new neuroprotectant which blocks N-methyl-D-aspartate responses
7. Activation kinetics reveal the number of glutamate and glycine binding sites on the N-methyl-D- aspartate receptor
8. Effect of CP101,606, a novel NR2B subunit antagonist of the N-methyl- D-aspartate receptor, on the volume of ischemic brain damage off cytotoxic brain edema after middle cerebral artery occlusion in the feline brain
9. Ro 25-6981, a highly potent and selective blocker of N-methyl-D- aspartate receptors containing the NR2B subunit. Characterization in vitro
10. The neuroprotective action of dizocilpine (MK-801) in the rat middle cerebral artery occlusion model of focal ischaemia
11. NMDA receptor antagonists: Past disappointments and future prospects as neuroprotective agents
12. Ifenprodil and SL 82.0715 as cerebral anti-ischemic agents. I Evidence for efficacy in models of focal cerebral ischemia
13. Generation and characterisation of stable cell lines expressing recombinant human N-methyl-D-aspartate receptor subtypes
14. Lack of effect of L-687,414 ((+)-cis-4-methyl-HA-966), an NMDA receptor antagonist acting at the glycine site, on cerebral glucose metabolism and cortical neuronal morphology
15. The glycine binding site of the N-methyl-D-aspartate receptor subunit NRI: Identification of novel determinants of co-agonist potentiation in the extracellular M3-M4 loop region
16. NMDA receptor antagonists
17. A novel mechanism of activity-dependent NMDA receptor antagonism describes the effect of ifenprodil in rat cultured cortical neurones
18. State-dependent NMDA receptor antagonism by Ro 8-4304, a novel NR2B selective, non-competitive, voltage-independent antagonist
19. Molecular determinants of agonist discrimination by NMDA receptor subunits: Analysis of the glutamate binding site on the NR2B subunit
20. Evidence for a tetrameric structure of recombinant NMDA receptors
21. Clinical trials for acute cerebral ischaemia
22. Cerestat and other NMDA antagonists in ischemic stroke
23. N-Methyl-D-aspartic acid receptor structure and function
24. Development of the NMDA ion-channel blocker, aptiganel hydrochloride, as a neuroprotective agent for acute CNS injury
25. Identification of molecular determinants that are important in the assembly of N-methyl-D-aspartate receptors
26. CP-101,606, a potent neuroprotectant selective for forebrain neurons
27. A double-blind, placebo-controlled study of the safety, tolerability and pharmacokinetics of CP-101,606 in patients with a mild or moderate traumatic brain injury
28. Developmental and regional expression in the rat brain and functional properties of four NMDA receptors
29. Clinical experience with excitatory amino acid antagonist drugs
30. In vitro binding properties in rat brain of [3H]Ro 25-6981, a potent and selective antagonist of NMDA receptors containing NR2B subunits
31. Pathological changes induced in cerebrocortical neurons by phencyclidine and related drugs
32. Pharmacological properties of recombinant human N-methyl-D-aspartate receptors comprising NRla/NR2A and NRla/NR2B subunit assemblies expressed in permanently transfected mouse fibroblast cells
33. Cooperative modulation of MK-801 binding to the N-methyl-D-aspartate receptor-ion channel complex by L-glutamate, glycine and polyamines
34. The messenger RNAs for the N-methyl-D-aspartate receptor subunits show region-specific expression of different subunit composition in the human brain
35. A model of proximal middle cerebral artery occlusion in rat
36. The behavioural effects of MK-801: A comparison with antagonists acting non-competitively and competitively at the NMDA receptor
37. Identification of amino acids in the N-methyl-D-aspartate receptor NR1 subunit that contribute to the glycine binding site
38. Distinct spatio-temporal distributions of the NMDA receptor channel subunit mRNAs in the brain
39. NMDA receptor heterogeneity during postnatal development of the rat brain: Differential expression of the NR2A, NR2B and NR2C subunit proteins
40. Ifenprodil discriminates subtypes of the N-methyl-D-aspartate receptor: Selectivity and mechanisms at recombinant heteromeric receptors
41. Determination of the N-methyl-D-aspartate receptor NR2B subunit blocker Ro 63-1908 in rat, cynomolgus monkey and human plasma by high-performance liquid chromatography with column switching and fluorescence detection
42. 4-Hydroxy-l-[2-(4- hydroxyphenoxy)ethyl]-4-(4-methylbenzyl)piperidine: A novel, potent and selective NR1/2B NMDA receptor antagonist